GMP Cell Therapy Consumables Market Size & Growth | 2028

GMP Cell Therapy Consumables Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and  Research)

Publication Month : Nov 2022

  • Report Code : TIPRE00029780
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 220
Inquire Before Buy



The GMP cell therapy consumables market is expected to grow from US$ 11,031.25 million in 2021 to US$ 59,985.89 million by 2028; it is estimated to grow at a CAGR of 27.5% from 2022 to 2028.

The GMP cell therapy consumables market is segmented on the basis of product, cell therapy, process, end use, and regions. The report offers insights and in-depth analysis of the market, emphasizing various parameters such as dynamics, trends, and opportunities of the market and competitive landscape analysis of leading market players across various regions. It also includes the impact analysis of COVID–19 pandemic across the regions.

Market Insights

Rise in Research & Development and Drug Discovery Drive Market Growth

Drug discovery is a long process that comprises various steps such as early discovery, preclinical phase, clinical phase, and regulatory approval. The process tremendously involves the use of cell therapy consumables to achieve the desired results. According to the World Health Organization, ~10 million deaths due to cancer were recorded in 2020, and the most common cancers are breast, lung, colon, rectum, and prostate cancers. Various research studies have shown positive outcomes of drugs that can effectively treat cancer, neurological disorders, autoimmune disorders, and other chronic disorders. Therefore, the rising prevalence of chronic disorders propels the demand for research and development (R&D) activities.

Moreover, numerous biotechnology companies operating in the market are collaborating with each other to accelerate R&D activities on a global level. For instance, in October 2022, Century Therapeutics and Bristol Myers Squibb announced the research collaboration and license agreement to develop and commercialize up to four induced pluripotent stem cells (“iPSC”) derived, engineered natural killer cell (“iNK”) and/or T cell (“iT”) programs for hematologic malignancies and solid tumors. Additionally, the rising demand for personalized and regenerative medicine has further boosted the growth of the cell therapy consumables market. An increase in drug discovery and R&D requires good manufacturing practices, and GMP consumables are required to obtain desired results from these activities. Thus, an increase in research & development activities, along with a surge in drug discovery, has increased the use of GMP cell therapy consumables.

GMP Cell Therapy Consumables Market -

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

GMP Cell Therapy Consumables Market: Strategic Insights

Market Size Value inUS$ 11,031.25 Million in 2021
Market Size Value byUS$ 59,985.89 Million by 2028
Growth rateCAGR of 27.5% from 2022 to 2028
Forecast Period2022-2028
Base Year2021
Analyst Image


Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Product-Based Insights

Based on product, the GMP cell therapy consumables market is segmented into kits, reagents/molecular biology reagents, growth factors/cytokines and interleukins, and others. In 2021, the kits segment held the largest market share. However, the growth factors/cytokines and interleukins segment are anticipated to register the highest CAGR in the market during 2022–2028. Reagents and supplements specifically designed for cell culture allow the growth and propagation of a wide spectrum of cell types under controlled conditions. TheraPEAK Products include an array of GMP buffers and reagents dedicated to the creation and development of cell and gene therapies. They are mainly produced in ISO: 13485 plants, such that these GMP solutions for cell and gene therapy are used by various customers in numerous clinical applications. There can be various types of molecular biology reagents that are GMP compliant in nature and mainly used in academics and clinical settings.

GMP Cell Therapy Consumables Market, by Product – 2021–2028

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Cell Therapy-Based Insights

Based on cell therapy, the GMP cell therapy consumables market is segmented into NK cell therapy, stem cell therapy, T-cell therapy, and others. In 2021, the T-cell therapy segment held the largest share of the market. However, the market in the NK cell therapy segment is expected to grow at the fastest rate during the forecast period. Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy used to treat certain types of cancer, especially blood cancer or leukemia. The therapy capitalizes the power of immune system protecting against the infections and illnesses by destroying harmful invaders, such as viruses and bacteria. Various research and clinical trials on CAR T-cell therapy are being conducted for cancer treatment. For instance, in January 2022, a new CAR T-cell therapy was developed by University College London (UCL) researchers. Phase-I clinical trials of this therapy carried out at UCL Hospitals (UCLH) concluded that this therapy has fewer toxic effects and is durable. Such increasing clinical trials of CAR T-cell therapy are surging the demand for GMP cell therapy consumables.

Process-Based Insights

Based on process, the GMP cell therapy consumables market is segmented into cell collection and characterization/sorting and separation, cell culture and expansion/preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution/handling, process monitoring and control/readministration/quality assurance, and others. In 2021, the cell collection and characterization/sorting and separation segment held the largest share of the market. However, the GMP cell therapy consumables market in the cryopreservation segment is expected to grow at the fastest rate during the forecast period. Cell characterization is crucial for understanding the intrinsic factors involved in cellular proliferation, function, and overall process. Cells are sorted and separated based on these characteristics. Companies are building the GMP compliant cell sorter to avoid contamination during the process. For instance, Miltenyi Biotec sells MACSQuant Tyto Cell Sorter, a sterile and GMP compliant multiparametric cell sorting in a closed cartridge system. The company also provides a certificate of analysis (CoA), certificate of origin (CoO), and product information files (PIF) for the regulatory approval of cell manufacturing protocols.

End Use-Based Insights

Based on end use, the GMP cell therapy consumables market is segmented into clinical, commercial, and research. In 2021, the clinical segment held the largest share of the market. Also, the GMP cell therapy consumables market in the same segment is expected to grow at the fastest rate during the forecast period. In clinical use, cell therapy research is carried out on people to evaluate medical, surgical, or behavioral intervention of a particular therapy. Clinical trials are expanding due to the rising prevalence of chronic disorders, , increasing biologics, and rising number of contract research organizations undertaking clinical studies. Various cell therapies are expected to achieve market authorization in the coming years. According to a Nature article, 2,073 active cell therapy agents were in the pipeline in April 2021, which was 572 more than the 2020 update.

The GMP cell therapy consumables market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio across the world and meet the growing demand. Inorganic growth strategies witnessed in the market are partnerships and collaborations. These growth strategies have allowed the market players to expand their businesses and enhance their geographic presence. Additionally, acquisitions, partnerships, and other growth strategies help strengthen the company’s customer base and increase its product portfolio.

  • In January 2021, Sartorius signed a strategic collaboration with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC). The collaboration advanced the scale-up of hMSC manufacturing for regenerative medicine. RoosterBio and Sartorius created a set of GMP-compatible, customer-centric protocols using RoosterBio’s hMSC and media systems alongside Sartorius’s single-use manufacturing technologies, process control software, and cell analysis tools of hMSC final product manufacturing.
  • In September 2020, Bio-Techne Corporation opened an ~61,000 square foot state-of-the-art Good Manufacturing Practices (GMP) manufacturing facility. Located in St. Paul, MN, the new facility is dedicated to support large-scale production of GMP-grade materials, which are an essential component for many immuno-oncology and regenerative medicine cell and gene-modified therapy workflows. This facility helps the company meet current and future demand for the GMP-grade reagents that are necessary to support the rapidly growing cell therapy market.

GMP Cell Therapy Consumables Market - Company Profiles

  • Sartorius AG                             
  • Thermo Fisher Scientific Inc         
  • Miltenyi Biotec BV & Co KG          
  • Bio-Techne Corp                        
  • Corning Inc                               
  • FUJIFILM Irvine Scientific Inc        
  • Lonza Group AG                        
  • BPS Bioscience Inc                     
  • Merck KGaA                              
  • Global Life Sciences Solutions USA LLC.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Product, Cell Therapy, Process, and End Use

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions

What are GMP cell therapy consumables?

Good Manufacturing Practices (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards. Cell therapy manufacturing processes range in complexity. Cell therapy manufacturing processes require an underpinning pharmaceutical quality system and quality control (QC) laboratory, and all aspects of cell therapy manufacturing require trained personnel. As the process is complex there may be chances of contamination, therefore GMP in cell therapy is becoming mandatory. Also, the use of cell therapy for treatment of various diseases is increasing the demand for cell therapy consumables that are manufactured according to GMP regulations.

What are the driving factors for the global GMP cell therapy consumables worldwide?

The factors driving the growth of GMP cell therapy consumables are Increase in research & development and drug discovery, as well as increase in strategic collaborations.

What are the restraining factors for the global GMP cell therapy consumables worldwide?

Stringent regulatory policies are expected to restrict the GMP cell therapy consumables growth during the forecast period.

Who are the major players in GMP cell therapy consumables across the globe?

The GMP cell therapy consumables majorly consist of the players, such as Sartorius AG, Thermo Fisher Scientific Inc, Miltenyi Biotec BV & Co KG, Bio-Techne Corp, Corning Inc, FUJIFILM Irvine Scientific Inc, Lonza Group AG, BPS Bioscience Inc, Merck KGaA, and Global Life Sciences Solutions USA LLC among others.

Which segment is dominating the GMP cell therapy consumables market?

The global GMP cell therapy consumables based on the product are segmented into kits, reagents/molecular biology reagents, cell culture media and supplements, growth factors/cytokines and interleukins (including protein and nucleic acid purification buffers), and others. The kits segment held the largest market share in 2021. However, growth factors/cytokines and interleukins is anticipated to register the highest CAGR during the forecast period.

Which region is dominating the GMP cell therapy consumables market?

The global GMP cell therapy consumables based on regions is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In 2021, the North American area held the largest market share. However, the Asia Pacific region is estimated to grow at the fastest CAGR of 29.6% during the forecast period

The List of Companies - GMP Cell Therapy Consumables Market

  1. Sartorius AG
  2. Thermo Fisher Scientific Inc
  3. Miltenyi Biotec BV & Co KG
  4. Bio-Techne Corp
  5. Corning Inc
  6. FUJIFILM Irvine Scientific Inc
  7. Lonza Group AG
  8. BPS Bioscience Inc
  9. Merck KGaA
  10. Global Life Sciences Solutions USA LLC

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports